Multimedia symposium on anemia management in dialysis patients posted on the Web

Chicago 05 April 1999 The Internet electronic journal HDCN has posted a multimedia symposium about anemia monitoring in dialysis patients on the Web. The abbreviation HDCN stands for Hypertension, Dialysis, and Clinical Nephrology. The symposium contents focuses in detail on the administering of intravenous iron preparations to hemo-dialysis patients. The five lectures were originally presented at a Satellite Symposium to the 31st edition of the American Society of Nephrology's Annual Meeting. The event was supported by a grant from Schein Pharmaceutical Inc.

Advertisement

The Internet electronic journal HDCN has posted a multimedia symposium about anemia monitoring in dialysis patients on the Web. The abbreviation HDCN stands for Hypertension, Dialysis, and Clinical Nephrology. The symposium contents focuses in detail on the administering of intravenous iron preparations to hemo-dialysis patients. The five lectures were originally presented at a Satellite Symposium to the 31st edition of the American Society of Nephrology's Annual Meeting. The event was supported by a grant from Schein Pharmaceutical Inc.

The symposium includes the description of a United States study evaluating the new iron preparation Ferrlecit that consists of a sodium ferric gluconate complex in sucrose injection. Ferrlecit will soon be marketed in the United States by Schein Pharmaceutical Inc. This kind of intravenous iron preparations is used in hemo-dialysis patients with anemia to increase the effectiveness of erythropoietin, which is manufactured by Amgen Inc. All details are to be found in the Anemia Management Symposium file.

Other Satellite Symposia posted on HDCN from the 31st meeting of the American Society of Nephrology include:

  1. "Highlights from Strategies for Improving Outcomes in Pre-ESRD and ESRD Patients", supported by a grant from Baxter Healthcare
  2. " Hyperphosphatemia: Clinical Complications and Management in 1998", supported by a grant from Genzyme Inc.
The latter symposium discusses innovative therapeutic approaches for the treatment of hyperphosphatemia in chronic renal failure, including a new drug developed by Geltex Pharmaceuticals and marketed by Genzyme Inc., called Renagel, a calcium-free, aluminum-free, phosphorus binder.

The e-journal HDCN is targeted to physicians, nurses, and other health professionals interested in hypertension, cardiovascular disease, and kidney dysfunctions. The publication is updated weekly with topic-specific links to clinically important journal articles and abstracts. Additionally, HDCN also posts multimedia symposia from various scientific meetings in synchronized slide/audio format with use of software from the RealNetworks Company. Currently, HDCN has posted more than 100 such multimedia symposia.

In November of 1998, Medtext Inc., publisher of HDCN, entered into a licensing agreement with the American Society of Nephrology and the Renal Physicians' Association to reproduce selected abstracts and symposia from these Societies' scientific meetings. The CME Credit Symposium on Acid-Base/Sodium Disorders offers a good example of this initiative.


Leslie Versweyveld

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]